Message from CEO
PPMX received 1.4 billion yen from Nippon Venture Capital Co.,Ltd. and other capitals in a third party allocation of shares.
Fujifilm initiates a Phase I clinical trial of the anti-cancer agent “FF-21101” (RI labeled antibody) in the United States. PPMX contributed to creating antibody based on antibody engineering technology.
PPMX receives JST Grant to develop Anti TfR antibody for Adult T-cell Leukemia.
Preclinical evaluation of RI labelled anti CDH3 antibody received First Place Poster Award at SNMMI2013.
Research progress of anti TFR antibody for solid tumor was reported at AACR2013.
Research progress of new RI labelled therapeutic antibody was reported at SNM2010
Research progress of anti CDH3 antibody was reported at AACR2010
PPMX received one billion yen from FUJIFILM in a third-party allocation of shares, and became a subsidiary company of Fuji Film.
Perseus Proteomics starts selling “Human Pentraxin3/TSG-14 ELISA System” worldwide
Perseus Proteomics, Inc. announces Collaborative Agreement for Research on "PTX3 as a cardiovascular risk predictor"
Research progress regarding the "Vascular Injury marker Pentraxin 3(PTX3)" will be presented at Digestive Disease Week 2007
Research progress regarding the "Vascular Injury marker Pentraxin 3(PTX3)" will be presented at The 51st Annual General Assembly and Scientific Meeting of Japan College of Rheumatology
Development of Cystatin SN as a new diagnostic marker for colon cancer Reported at The 93rd Annual Meeting of the Japanese Society of Gastroenterology
Research progress regarding the " Vascular Injury marker Pentraxin 3(PTX3)" will be presented at The American college of cardiology held on March 24-27th, 2007 in New Orleans.
Research progress regarding the "Vascular Injury marker Pentraxin 3(PTX3)" will be presented at The 71st Annual Scientific Meeting of the Japanese Circulation Society held on March 15-17th, 2007 in Kobe.
Our Collaboration Research results regarding "The Vascular Injury Marker PTX3" and "Research in Nuclear Hormone Receptors" will be presented at the 96th Annual Pathology Meeting.
Our scientific article using Perseus Proteomics human ELISA system "Establishment of a High Sensitivity Plasma Assay for Human Pentraxin3 as a Marker for Unstable Angina Pectoris" was just published.
Perseus Proteomics and Chugai Pharmaceutical reach purchase and sales agreement on glypican-3 therapeutic antibody.
Perseus Proteomics Inc. Now Offers High Sensitivity Monoclonal Antibodies against All 48 of the Nuclear Hormone Receptors
Perseus Proteomics Inc. announces its participation in the New Energy and Industrial Technology Development Organization (NEDO) government sponsored research project entitled "The Technical Development of New Functional Antibodies"
Invited to Participate in NEDO Sponsored Government Project for the development of a Bionanochip for the Analysis of Protein Interactions Project (Focus 21)
Perseus Proteomics Inc. Announces the Appointment of Dr. Toshiyo Tanaka and Dr. Patrick C. Reid to the Scientific Advisory Board.
Fuji Photo Film Co., Ltd. Makes Equity Investment in Perseus Proteomics Inc.